Ipamorelin is a selective growth hormone secretagogue that stimulates a clean, physiological GH pulse with minimal cortisol or prolactin elevation. It is considered the first-line GHRP for beginners and is most effective when combined with a GHRH like CJC-1295.
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.
Overview
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist composed of 5 amino acids. It is one of the cleanest and most selective GH-releasing peptides studied to date — it stimulates a strong, physiological pulse of growth hormone without triggering meaningful releases of cortisol, prolactin, or ACTH that are common with older GHRP compounds. For these reasons, ipamorelin is typically considered the first-line GHRP for beginners and is one of the most commonly combined peptides in the Sleep & GH category.
Mechanism of Action
Ipamorelin binds to and activates the growth hormone secretagogue receptor (GHSR-1a) — the ghrelin receptor — in the anterior pituitary gland. This triggers a sharp, pulsatile release of endogenous growth hormone that mimics the body's natural nocturnal GH pulse pattern. Unlike GHRP-2 and GHRP-6, ipamorelin has high receptor selectivity: it activates GHSR-1a without significantly stimulating receptors for ACTH (adrenocorticotropic hormone) or prolactin, resulting in minimal cortisol or prolactin elevation at therapeutic doses. Ipamorelin also mildly inhibits somatostatin (the hormone that suppresses GH release), which extends the duration of GH secretion following each dose. The resulting GH pulse stimulates hepatic production of IGF-1 (insulin-like growth factor 1), which mediates many of the downstream anabolic, lipolytic, and recovery effects.
Key Research
Ipamorelin was developed by NovaNordisk (NNC 26-0161) and demonstrated selective GH release with minimal cortisol and prolactin elevation in rodent and primate studies. Phase II clinical trials assessed its safety and efficacy in postoperative ileus patients. Multiple clinical studies confirmed ipamorelin produces GH pulses 2–3x physiological baseline with no meaningful ACTH stimulation at therapeutic doses — a key advantage over GHRP-2 and GHRP-6. Studies in elderly subjects showed restoration of age-related GH decline without HPA axis disruption. It has been evaluated for IGF-1 normalization in GH-deficient adults in European clinical research.
The standard research dose is 100–300 mcg per injection, administered subcutaneously. Ipamorelin is most commonly dosed 2–3 times daily: once in the morning upon waking (fasted), once pre-workout (30–45 minutes before training), and once before bed. The pre-bed dose is considered the most effective as it amplifies the natural nocturnal GH pulse. For best results, doses should be taken in a fasted state or at least 2 hours after a carbohydrate-containing meal, as insulin elevation blunts GH release. Standard cycle length is 8–12 weeks. Ipamorelin is almost always combined with a GHRH (Growth Hormone Releasing Hormone) such as CJC-1295 or Sermorelin for synergistic GH amplification.
Classic Beginner Stack: Ipamorelin 200 mcg + CJC-1295 (no DAC) 100 mcg injected together twice daily (morning + pre-bed) for 12 weeks. Advanced GH Stack: Ipamorelin 300 mcg 3x daily + CJC-1295 DAC 2 mg twice weekly for 16 weeks. Anti-Aging Protocol: Ipamorelin 100–150 mcg once nightly before bed for 6-month continuous use, focusing on sleep quality, body composition, and collagen support.
Reported Side Effects
Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
Ipamorelin is notable for its minimal side effect profile. The most commonly reported effect is a temporary, mild headache or head rush immediately following injection, caused by a brief drop in blood sugar as GH elevation stimulates glucose uptake. Water retention (subcutaneous bloating) can occur with higher doses or extended cycles, particularly in the hands, feet, and ankles. Mild tingling or numbness in the extremities (similar to carpal tunnel symptoms) is occasionally reported at higher doses and typically resolves with dose reduction. Unlike GHRP-6, ipamorelin does not meaningfully increase appetite, making it preferable for individuals where appetite control is important. Prolactin and cortisol elevations are negligible at standard doses.
Storage & Handling
Store lyophilized powder at 2–8°C protected from light. Stable for 12–18 months as a lyophilized powder. Reconstitute with bacteriostatic water: a 5 mg vial with 2 mL BAC water yields a 2,500 mcg/mL concentration. After reconstitution, store refrigerated at 2–8°C and use within 28 days. Never freeze reconstituted solution. Draw doses with a standard U-100 insulin syringe.
Age Verification Required
This site contains information about research peptides intended for adults 21 and older. By continuing you confirm you are of legal age in your jurisdiction.
By confirming below, you agree that you are at least 21 years of age and legally able to access this content in your jurisdiction.
Access Restricted
We're sorry, but you must be at least 21 years of age to access this site. This content contains research information intended for adults only.
Research Disclaimer
RESEARCH USE ONLY: All information, tools, and resources on Peptide Oracle are for educational and research purposes only.
Not Medical Advice: Nothing on this website constitutes medical advice, diagnosis, or treatment. This site does not replace professional medical consultation.
Not for Human Consumption: Peptides discussed are for laboratory and research purposes only. They are not approved for human use, consumption, or self-administration.
No Therapeutic Claims: We make no claims regarding the safety, efficacy, or therapeutic benefits of any peptides or compounds discussed.
Legal Compliance: You are responsible for compliance with all applicable local, state, and federal laws regarding peptide research and acquisition.
Limitation of Liability: Peptide Oracle assumes no liability for any damages resulting from use of information provided on this site.
Saved for 30 days. Reset by clearing browser data.
We use cookies to improve your experience and analyse site usage. By clicking Accept All you consent to our use of cookies. Cookie Policy
